• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Xanthine oxidase inhibitors in elderly patients with heart failure: useful or useless?

作者信息

Presta Vivianne, Citoni Barbara, Tocci Giuliano

机构信息

Hypertension Unit, Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy.

IRCCS Neuromed, Pozzilli, IS, Italy.

出版信息

Intern Emerg Med. 2019 Sep;14(6):903-905. doi: 10.1007/s11739-019-02105-4. Epub 2019 May 13.

DOI:10.1007/s11739-019-02105-4
PMID:31087252
Abstract
摘要

相似文献

1
Xanthine oxidase inhibitors in elderly patients with heart failure: useful or useless?老年心力衰竭患者中的黄嘌呤氧化酶抑制剂：有用还是无用？
Intern Emerg Med. 2019 Sep;14(6):903-905. doi: 10.1007/s11739-019-02105-4. Epub 2019 May 13.
2
Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.黄嘌呤氧化酶抑制剂使用者与非使用者以及非布司他使用者与别嘌醇使用者的心血管风险比较。
Rheumatology (Oxford). 2020 Sep 1;59(9):2340-2349. doi: 10.1093/rheumatology/kez576.
3
Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment.兔心肌梗死后长期黄嘌呤氧化酶抑制：早期治疗与延迟治疗的效果
Life Sci. 2008 Feb 27;82(9-10):495-502. doi: 10.1016/j.lfs.2007.12.010. Epub 2008 Jan 24.
4
The Role of Xanthine Oxidase Inhibitors in Patients with History of Stroke: A Systematic Review.黄嘌呤氧化酶抑制剂在有中风病史患者中的作用：一项系统评价。
Curr Vasc Pharmacol. 2018;16(6):583-588. doi: 10.2174/1570161115666170919183657.
5
Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients.别嘌醇和非布司他对老年心力衰竭患者心血管死亡率的影响。
Intern Emerg Med. 2019 Sep;14(6):949-956. doi: 10.1007/s11739-019-02070-y. Epub 2019 Mar 12.
6
The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.黄嘌呤氧化酶抑制剂对慢性心力衰竭合并高尿酸血症患者的影响：托匹司他与别嘌醇对比的前瞻性随机对照临床试验——研究方案
Clin Exp Nephrol. 2018 Dec;22(6):1379-1386. doi: 10.1007/s10157-018-1599-6. Epub 2018 Jun 18.
7
Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 Inhibitors.尿酸是心力衰竭中氧化应激的生物标志物：来自别嘌醇和 SGLT2 抑制剂试验的经验教训。
J Card Fail. 2020 Nov;26(11):977-984. doi: 10.1016/j.cardfail.2020.08.015. Epub 2020 Sep 3.
8
Delayed treatment effects of xanthine oxidase inhibition on systolic overload-induced left ventricular hypertrophy and dysfunction.黄嘌呤氧化酶抑制对收缩期负荷过重诱导的左心室肥厚和功能障碍的延迟治疗效果。
Nucleosides Nucleotides Nucleic Acids. 2010 Jun;29(4-6):306-13. doi: 10.1080/15257771003738683.
9
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.非布司他：一种选择性黄嘌呤氧化酶/黄嘌呤脱氢酶抑制剂，用于治疗成人痛风患者的高尿酸血症。
Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033.
10
Class effect of xanthine oxidase inhibitors on flow-mediated dilatation in hypertensive patients: A randomized controlled trial.黄嘌呤氧化酶抑制剂对高血压患者血流介导扩张作用的类效应：一项随机对照试验。
J Clin Hypertens (Greenwich). 2020 Mar;22(3):451-456. doi: 10.1111/jch.13757. Epub 2019 Dec 24.

本文引用的文献

1
Cost-effectiveness analysis of different hypertension management strategies.不同高血压管理策略的成本效益分析
Intern Emerg Med. 2020 Mar;15(2):181-182. doi: 10.1007/s11739-019-02153-w. Epub 2019 Jul 18.
2
Uric acid and risk of new-onset metabolic syndrome, impaired fasting glucose and diabetes mellitus in a general Italian population: data from the Pressioni Arteriose Monitorate E Loro Associazioni study.尿酸与新发代谢综合征、空腹血糖受损和糖尿病风险在一般意大利人群中的关系：来自动脉血压监测及其关联研究的数据。
J Hypertens. 2018 Jul;36(7):1492-1498. doi: 10.1097/HJH.0000000000001721.
3
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
别嘌醇或非布司他治疗痛风患者的心血管安全性。
N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12.
4
Uric acid as an independent predictor of coronary artery disease in essential hypertension: Data from an 8-year-follow-up study.尿酸作为原发性高血压患者冠状动脉疾病的独立预测因子：一项为期 8 年的随访研究数据。
Clin Exp Pharmacol Physiol. 2018 Aug;45(8):866-869. doi: 10.1111/1440-1681.12928. Epub 2018 Mar 23.
5
The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo-controlled, double-blind, crossover trial.非布司他对冠心病患者冠状动脉内皮功能障碍的影响：一项 4 期随机、安慰剂对照、双盲、交叉试验。
Am Heart J. 2018 Mar;197:85-93. doi: 10.1016/j.ahj.2017.11.006. Epub 2017 Nov 23.
6
Serum uric acid levels and outcome during admission in acute ischaemic stroke, depending on renal function.急性缺血性卒中住院期间的血清尿酸水平及预后，取决于肾功能。
Int J Neurosci. 2018 Oct;128(10):906-912. doi: 10.1080/00207454.2018.1441150. Epub 2018 Feb 26.
7
Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observational Study.尿酸与心血管疾病的探索：尿酸对心脏健康有益（URRAH）项目，一项回顾性观察性研究的研究方案
High Blood Press Cardiovasc Prev. 2018 Jun;25(2):197-202. doi: 10.1007/s40292-018-0250-7. Epub 2018 Feb 9.
8
The association of uric acid with the risk of metabolic syndrome, arterial hypertension or diabetes in young subjects- An observational study.尿酸与年轻人群代谢综合征、动脉高血压或糖尿病风险的相关性：一项观察性研究。
Clin Chim Acta. 2018 Mar;478:68-73. doi: 10.1016/j.cca.2017.12.038. Epub 2017 Dec 24.
9
Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: The British Regional Heart Study.血清尿酸作为降压治疗男性心力衰竭风险的潜在标志物：英国区域心脏研究。
Int J Cardiol. 2018 Feb 1;252:187-192. doi: 10.1016/j.ijcard.2017.11.083. Epub 2017 Nov 28.
10
The association between uric acid levels and different clinical manifestations of coronary artery disease.尿酸水平与冠状动脉疾病不同临床表现之间的关联。
Coron Artery Dis. 2018 May;29(3):194-203. doi: 10.1097/MCA.0000000000000593.